Key result
BNP and NT-proBNP levels were markedly elevated during acute decompensated heart failure in a patient on Sacubitril/Valsartan, showing a parallel return to baseline after clinical improvement.
Why the study?
BNP and NT-proBNP evolve differently in chronic heart failure patients with reduced ejection fraction treated with sacubitril/valsartan, but how this translates during acute decompensation is unknown.
Does the evolution of BNP and NT-proBNP differ during acute decompensated heart failure in a patient treated with Sacubitril/Valsartan?
Case Report (n=1)
Does the evolution of BNP and NT-proBNP differ during acute decompensated heart failure in a patient treated with Sacubitril/Valsartan?
Both BNP and NT-proBNP retain similar diagnostic value for acute decompensated heart failure in patients treated with Sacubitril/Valsartan, showing parallel changes.
May support natriuretic peptide monitoring during decompensation on Sac/Val; leaves open generalizability from single case report.
BACKGROUND: B-type natriuretic peptide (BNP) and the N-terminal proBNP (NT-proBNP) exhibit different evolution in chronic heart failure patients with reduced ejection fraction treated with Sacubitril/Valsartan; BNP increasing or remaining stable, while NT-proBNP decreases. However, how this difference translates upon acute decompensation is unknown. CASE SUMMARY: Herein, we described in a 78-year-old woman with chronic heart failure with reduced ejection fraction treated with Sacubitril/Valsartan who had acute decompensated heart failure (ADHF). BNP and NT-proBNP were markedly high during ADHF and showed parallel return to baseline level after clinical improvement. DISCUSSION: BNP and NT-proBNP retained similar value for the diagnosis of ADHF in patient treated with Sacubitril/Valsartan. These findings strongly suggest that either BNP or NT-proBNP can be used indifferently in this context, while their relative use is debated in chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Tiepolo et al. (2019) conducted a case report in Acute decompensated heart failure (n=1). Sacubitril/Valsartan was evaluated on Evolution of B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP). BNP and NT-proBNP levels were markedly elevated during acute decompensated heart failure in a patient on Sacubitril/Valsartan, showing a parallel return to baseline after clinical improvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: